- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00821496
Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects
November 30, 2009 updated by: VIVUS LLC
A Phase I, Open Label, Fixed Sequence, Single-Center Study to Evaluate the Effect of Multiple Dose Administration of VI-0521 on the Pharmacokinetics of a Single Dose of Oral Contraceptive in Healthy Female Subjects
This study is desgigned to look at the effect of multiple dosing administration of VI-0521 on Oral Contraceptive medication.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is designed to determine if multiple oral doses of VI-0521 would alter the pharmacokinetics of an oral contraceptive in healthy female subjects.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85283
- MDS Pharma Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 64 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Females, 19 - 64 years of age (inclusive), who are non-pregnant, not planning pregnancy and non-breast-feeding.
- If females of child-bearing potential, be using adequate contraception, defined as double barrier methods, single barrier plus tubal ligation.
- A body weight of at least 50 kg and a body mass index (BMI) between 27 and 35 kg/m2, inclusive.
- Medically healthy, with clinically insignificant screening results.
- Subjects are able to communicate with the investigator, and to understand and comply with all requirements of study participation.
- Voluntarily consent to participate in the study.
Exclusion Criteria:
- A history or presence of significant cardiovascular, neurological, hematological, psychiatric, hepatic, gastrointestinal, pulmonary, endocrine, immunologic or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs or place the subjects at increased risk as determined by the investigator.
- Any clinically significant laboratory abnormalities as judged by the investigator.
- Any history of glaucoma, increased intraocular pressure, or medications to treat increased intraocular pressure.
- Presence of cholelithiasis or cholecystitis within the last 6 months that has not been surgically treated with cholecystectomy.
- Any history of a cardiovascular or cerebrovascular event.
- Systolic blood pressure > 150 mm Hg or diastolic blood pressure > 95 mm Hg at screening or at check-in on Day -1.
- Positive urine drug test, serum cotinine test, pregnancy test and/or positive urine alcohol test at screening or check in Day -1.
- Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV) at screening.
- Any history or presence of alcoholism or drug or substance abuse as defined by the investigator.
- Any active malignancy except basal cell carcinoma.
- A history of breast cancer.
- Any history of bipolar disorder or psychosis, history of psychiatric hospitalization, greater than one lifetime episode of major depression.
- A history of intolerance to oral contraceptives.
- A history of hypersensitivity or idiosyncratic reaction to the active drugs, compounds related to the study drugs or to any excipients present in the VI-0521 capsule.
- Use of any prescription or over-the-counter (OTC) medication, including herbal products, within the 14 days prior to Day -1. Up to 2 g per day of acetaminophen is allowed at the discretion of the Investigator.
- Use of any drug known to have a significance in inhibiting or inducing liver enzymes involved in drug metabolism [CYP P450]) within 30 days prior to Day -1.
- Blood donation or significant blood loss within 56 days prior to Day -1.
- Plasma donation within 7 days prior to Day -1.
- Any use of tobacco or nicotine products within 3 months prior to Day -1.
- Any history of celiac diseases, food allergies, and those on vegetarian or other diets incompatible with study objectives.
- Any subject who received an investigational drug within 30 days or six half-lives, whichever is longer, prior to dosing in this study.
- Clinical judgment by the investigator that the subject should not participate in the study.
- Involvement in the planning and conduct of the study.
- Any subject who has participated in a previous clinical trial with VI-0521.
- Subjects with any condition possibly affecting drug absorption.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oral Contraceptive
|
Oral contraceptive
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PK of the Oral contraceptive agent
Time Frame: 31 days
|
31 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
saftey and tolerability of multiple dose adminstration of VI-0521 in healthy female subjects
Time Frame: 31
|
31
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Shiyin Yee, VIVUS LLC
- Principal Investigator: Scott Sharples, M.D., MDS Pharma Services
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
March 1, 2009
Study Completion (Actual)
April 1, 2009
Study Registration Dates
First Submitted
January 6, 2009
First Submitted That Met QC Criteria
January 9, 2009
First Posted (Estimate)
January 13, 2009
Study Record Updates
Last Update Posted (Estimate)
December 2, 2009
Last Update Submitted That Met QC Criteria
November 30, 2009
Last Verified
November 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral, Combined
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Estradiol
- Ethinyl Estradiol
- Norethindrone
- Norethindrone Acetate
- Norinyl
Other Study ID Numbers
- OB-108
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on ethinyl estradiol, norethindrone, VI-0521
-
The Jones InstituteUnknownPostpartum Depressive Mood | Postpartum Sexual FunctionUnited States
-
Warner ChilcottCompleted
-
Teva Pharmaceuticals USACompletedBioequivalenceUnited States
-
Teva Pharmaceuticals USACompleted
-
University of Texas Southwestern Medical CenterCompleted
-
Warner ChilcottCompleted
-
NobelpharmaCompleted
-
Bristol-Myers SquibbCompletedHealthy Female VolunteersUnited States
-
Warner ChilcottCompleted
-
Warner ChilcottCompleted